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Background: The bone morphogenetic family proteins (BMP) are phytogenetically conserved proteins, which are
essential for embryonic development. The key regulatory subunit, the bone morphogenetic protein 4 (BMP4), is
overexpressed and associated with tumor metastasis in a variety of cancers. However, the prognostic and molecular
features of gliomas with BMP4 expression is still unclear.
Methods: We obtained whole genome mRNA expression microarray data of 220 glioma samples of all grades from
Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as discovery set. Of the 123 high-grade
gliomas in this set, 33 Grade III tumors and 88 GBMs were analyzed by Kaplan-Meier method. Immunohistochemistry
was used for validating the expression of BMP4 in another 77 glioma samples. Three additional datasets were
obtained as validation sets. Gene ontology (GO) analysis and gene set variation analysis (GSVA) were used for
functional annotation of BMP4.
Results: In the discovery set, BMP4 overexpression was significantly associated with low grade as well as the lower
mortality of high-grade gliomas in survival analysis (log-rank, p<0.05 in GBM patients and p<0.01 in anaplastic
gliomas, respectively). BMP4 also showed a Proneural subtype, G1 subtype and Isocitrate Dehydrogenase 1 (IDH1)
mutation preference and cell development association. The results of validation 4 datasets showed similar findings.
The overexpression of BMP4 was also detected in low grade gliomas compared to the high grade ones by
immunohistochemistry (p<0.05, chi-square test).
Conclusion: BMP4 expression was independently associated with grade and good prognosis in grade III and
grade IV gliomas, suggesting BMP4 as a novel biomarker with potential important therapeutic implications.
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Glioma is the most common type of brain tumor and is
an important cause of cancer related mortality among
adults and children [1]. It can be divided into low grade
glioma (LGG) and high grade glioma (HGG) depending
on the malignancy. The median survival of patients with
primary glioblastoma (GBM), the most malignant and
frequent type of glioma, is approximately 1 year. But be-
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reproduction in any medium, provided the orfrom <1 week to >3 years after diagnosis [2], suggesting
the limitations of the current diagnostic, predictive and
prognostic markers and better therapeutic strategies are
in the urgent need.
The introduction of molecular biomarkers in the man-
agement of patients with cancer may improve their clin-
ical outcomes. The bone morphogenetic family proteins
(BMP) are phytogenetically conserved proteins, which
are essential for embryonic development [3,4]. Their key
regulatory subunit, the bone morphogenetic protein 4
(BMP4), is overexpressed and associated with pathogen-
esis and metastasis in a variety of cancers [5-7]. How-
ever, the prognostic and molecular features of gliomas
with BMP4 expression is still unclear.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of 220 glioma patients
Grade II Grade III Grade IV
Median age 38 39 46
Male % 55.7 52.9 58.4
Median KPS 90 80 80
Median OS (days) ND 633 420
ND, not determined
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http://www.translational-medicine.com/content/11/1/100In this study, We obtained whole genome mRNA ex-
pression microarray data of 220 glioma samples of all
grades from Chinese Glioma Genome Atlas (CGGA)
database (http://www.cgga.org.cn) as discovery set [8]
and 3 additional previously published datasets as valid-
ation sets. After studying the expression level of BMP4
in these samples, we analyzed the prognostic value of it.
The expression difference was validated in another 77
glioma samples from Chinese Glioma Tissue Database
(CGTD) by Immunohistochemistry. We also performed
function annotation of BMP4 by GO analysis and GSVA,
which revealed its correlation with cell development, dif-
ferentiation and biogenesis.
Methods
Datasets used in this study
Whole genome mRNA expression microarray data and
clinical information of 220 glioma samples of all grades
from Chinese Glioma Genome Atlas (CGGA) database
[8] (http://www.cgga.org.cn) were obtained as discovery
set and 202 glioma expression files from the cancer gen-
ome atlas (TCGA) database [9] (http://cancergenome.
nih.gov), the Repository for Molecular Brain Neoplasia
Data (REMBRANDT, https://caintegrator.nci.nih.gov/rem-
brandt/) and GSE16011 data [10] (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE16011) were obtained
as validation sets.
Gene ontology (GO) analysis of BMP4 associated genes
After Pearson correlation analysis, gene ontology ana-
lysis of the positively correlated genes (r>0.4, p<0.05)Figure 1 The expression difference of BMP4 in LGG and HGG of CGGA
expression value of BMP4 of an individual patient. Lines in the middle werewere analyzed by DAVID (http://david.abcc.ncifcrf.gov/
home.jsp).
GSVA with BMP4 expression
Gene set variation analysis with BMP4 expression was
analyzed by GSVA package [11] of R [12]. Gene list was
obtained from GSVAdata package [13].
Immunohistochemistry (IHC)
Briefly, Immunoperoxidase staining for BMP4 (Abcam,
ab39973) were performed following the standard proto-
col recommended by the manufacturer. Each slide
stained for and BMP4 was individually reviewed and
scored by two independent observers. Discrepancies in
scoring between the two observers were resolved by
additional review of the specimens and discussion be-
tween the reviewers until a consensus was achieved. Ap-
proximately 15-20 fields at 400× magnification were
analyzed per specimen. The proportion of positively
stained tumor cells was graded as follows: 0, no positive
tumor cells; 1, <5% positive tumor cells; 2, 5-20%
positive tumor cells; and 3, >20% positive tumor cells.
The intensity of staining was recorded on a scale of 0
(no staining), 1 (weak staining, light yellow), 2 (moderate
staining, yellowish brown) and 3 (strong staining,
brown). The staining index was calculated as follows:
staining index = staining intensity × tumor cell staining
grade. High BMP4 expression was defined as a staining
index score ≥4, while low expression was defined as a
staining index <4.
Statistical analysis
For molecular subtype annotation of the 4 datasets, we
applied prediction analysis of microarrays (PAM) as pre-
viously reported [8]. Quantitative results were shown as
mean ± standard deviation. The difference of BMP ex-
pression was tested by the Student t-test in microarray
data and by chi-square test in IHC results. Overall sur-
vival time (OS) was calculated from the date of diagnosis
until death or the last follow-up. The survival curve ofand other two validation datasets. A single spot was the
the mean expression value.
Figure 2 IHC images of 2 distinct patients. A (LGG patient), showed high expression of BMP4 in cytoplasm; B (HGG patient), showed low
expression of BMP4. Magnification: larger images, ×200; smaller images, ×400.
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with the Kaplan-Meier method and the difference was an-
alyzed using the two-sided log-rank test. A p-value < 0.05
was considered statistically significant. All the data analysis
was performed in GraphPad Prism and R.
Written informed consent was obtained from the pa-
tient for publication of this report and any accompanying
images. The study was performed with the approval ofFigure 3 The prognostic value of BMP4 in CGGA and validation datas
BMP4 expression level, patients with anaplastic or GBM could be divided in
(B, C anaplastic gliomas and GBMs in CGGA data; E, F, anaplastic gliomas a
gliomas in GSE16011 data). For LGG patients, there is only marginal p value
expression of BMP4 than the median one. L, lower expression of BMP4 thaEthics Committee of Capital Medical University and was
in compliance with the Helsinki Declaration.
Results
Characteristics of patients included
Of the 220 glioma patients in the training set, there were
97 grade II gliomas (astrocytomas, oligodendrogliomas,
and oligoastrocytomas), 34 grade III gliomas (anaplasticets. Except for GBM patients in GSE16011 dataset (I), according to
to two groups with significantly different prognosis, respectively
nd GBMs in Rembrandt data; G, GBMs in TCGA data; H, anaplastic
(A, LGGs in CGGA data; D, LGGs in Rembrandt data). H, higher
n the median one.
Figure 4 BMP4 expression showed a Proneural, G1 subtypes and IDH1 mutation preference. For each patient, TCGA and CGGA subtype
were annotated as previously reported and listed in the upper part as well as the IDH1 mutation status, which was obtained from CGGA
database. The positively and negatively correlated genes were showed in the lower part (marked pink and blue in the right, respectively).
NA, not available.
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tic oligoastrocytomas) and 89 grade IV gliomas (GBMs).
Clinical information (age, gender, preoperational Karnofsky
Performance Scale (KPS) score, and treatment) were
obtained from medical records of CGGA database,
which were listed in Table 1.BMP4 was overexpressed in low-grade gliomas
After screening of differently expressed genes in the dis-
covery dataset, we found that BMP4 was in the list of
genes significantly differently expressed between LGGs
and HGGs. Both in CGGA and other 3 validation
datasets, the expression of BMP4 in LGG was higher
than that in HGG (Figure 1).The expression level of BMP4 was validated in an
independent group of patients by IHC
We further validated the protein expression level of BMP4
in an independent group of 77 glioma patients by IHC
(Figure 2). Similar to the findings above, BMP4 showed a
higher expression status in LGGs than that in HGGs
(p<0.05, chi-square test). Thus, BMP4 expression showed
a LGG preference both in mRNA and protein level.BMP4 was a better prognostic marker in anaplastic
gliomas and glioblastomas
We confirmed the prognosis of the 220 patients, and got
216 patients for further prognosis analysis (the prognosis
of 2 patients were not available and the OS of another 2
patients were too short which might due to other compli-
cations other than glioma). As is shown in Figure 3, both
anaplastic glioma (Figure 3B) and GBM (Figure 3C) pa-
tients with high or low expression of BMP4 had consid-
erable different prognosis. But there was only a marginal
p value in LGGs (Figure 3A). The results were similar in
the validation set (Figure 3D-I). Therefore, BMP4 was a
better prognostic marker in anaplastic gliomas and glio-
blastomas. The high or low expression was defined as
higher or lower than the median individual in each grade.
BMP4 expression showed a subtype preference
As BMP4 showed association with LGGs and better
prognosis, we screened its expression in different mo-
lecular subtypes of gliomas. As previously reported, we
annotated the 4 datasets by TCGA and CGGA classifica-
tion systems by PAM [8,9]. BMP4 showed a Proneural
and G1 subtype preference. Patients with IDH1 gene
mutation also showed higher expression of BMP4 than
Figure 5 The BMP4 expression was significantly different for different TCGA and CGGA subtypes and IDH1 mutation status. A, D, G and
H showed BMP4 had a Proneural preference. B, E and I showed BMP4 had a G1 preference. C and F showed that patients with IDH1 gene
mutation also showed higher expression of BMP4 than those with wild-type IDH1 gene. A single spot was the expression value of BMP4 of an
individual patient. Lines in the middle were the mean expression value.
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sion difference was shown in Figure 5.
BMP4 was associated with cell development
After Pearson correlation analysis of the data from
CGGA, the significantly positively correlated genes (Pink
marked genes in Figure 4) were used for GO analysis.
The top 20 GO terms listed in Table 2 showed that
BMP4 was associated with cell development, differenti-
ation and biogenesis.
The positive correlation of astrocytic genes and BMP4
As GO analysis showed that BMP4 had a tight association
with cell development, differentiation and biogenesis, es-
pecially astrocytes, we performed GSVA with BMP4 ex-
pression (Figure 6). Genes up- and down-regulated in
astrocytes went positively and negatively with BMP4 ex-
pression. Meanwhile, it has been reported that Proneuralgliomas are characterized by oligodentrocytic genes which
is in concordance with the present study [9]. Oligo-
dentrocytic genes were accumulated in patients with
higher BMP4 expression, which was preferentially
expressed in Proneural gliomas.
Discussion
Glioma is the most common lethal intracranial tumor in
adults. Even after years of efforts in developing and im-
proving therapeutic strategies, the glioma patients still
have a poor survival time. As the identification of novel
biomarkers and new molecular classification systems, we
really see the dawn of a new era.
The bone morphogenetic family proteins (BMP) are
highly conserved proteins, which are essential for
embryonic development. Since potent developmental
regulators are frequently disrupted in cancer [14], it is to
be expected that BMP4 also contributes to tumor
Table 2 Top 20 GO terms of BMP4 positively associated
genes
GO term Biological process
GO:0030509 BMP signaling pathway
GO:0048710 regulation of astrocyte differentiation
GO:0045685 regulation of glial cell differentiation
GO:0014013 regulation of gliogenesis
GO:0060284 regulation of cell development
GO:0048712 negative regulation of astrocyte differentiation
GO:0007386 compartment specification
GO:0007178 transmembrane receptor protein serine/threonine kinase
signaling pathway
GO:0006350 transcription
GO:0010721 negative regulation of cell development
GO:0016202 regulation of striated muscle tissue development
GO:0048634 regulation of muscle development
GO:0050767 regulation of neurogenesis
GO:0045449 regulation of transcription
GO:0045686 negative regulation of glial cell differentiation
GO:0014014 negative regulation of gliogenesis
GO:0051960 regulation of nervous system development
GO:0042474 middle ear morphogenesis
GO:0007507 heart development
GO:0007389 pattern specification process
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has been generated on the contribution of BMP family
members, such as BMP4, in cancer pathogenesis. Firstly,
BMP4 gene variants have been shown to predispose to
colorectal cancer [15]. Meantime, the expression level of
BMP4 are frequently altered in many tumor typesFigure 6 Gene set variation analysis with BMP4 expression. Gene expr
cultured astroglial cells were generated from GSVAdata package. The BMP4
indicates positive correlation with BMP4 expression and a low enrichment[5-7,16,17]. Both in vivo and in vitro studies have demon-
strated the role of BMP4 on suppression of cell growth
[18,19], induction to migration, invasion and epithelial-
mesenchymal transition [20,21], which are associated with
cancer metastasis and progression.
There are only limited reports on the role of BMP4 in
gliomas focusing on the anti-proliferation effect of
BMP4 to stem-like cells [22-25] and GBM cell lines [26].
In the present study, we found that BMP4 was over-
expressed in LGGs. The expression difference was vali-
dated by microarray data from other datasets and IHC
results from an independent group of patients from
CGTD. These results showed that BMP4 was a potential
marker for grading of gliomas.
Considering its effects on growth suppression, BMP4
has been suggested as a possible therapeutic target in can-
cer cells. Nevertheless, the other functional characteristics
of BMP4, especially the promotion of cell mobility, make
such strategies less appealing. Improved knowledge of the
downstream mediators of BMP4 effects in cancer cells
may allow dissection of the different BMP4 induced
phenotypes and thereby generation of specific targeted
therapies [27].
For prognosis analysis, we generated survival curve of
data from CGGA and 3 other datasets by Kaplan-Meier
method and the difference was analyzed using the two-
sided log-rank test. Patients with higher expression of
BMP4 showed a significantly better prognosis in ana-
plastic gliomas and GBMs. That exhibited the predomi-
nation of beneficial effects over detrimental effects of
BMP4 in gliomas. Hence, BMP4 showed its capacity to
be a better prognostic marker and a therapeutic target.
We also found the preference expression of BMP4 in
IDH1 mutation patients, Proneural subtype or G1ession signatures of oligodendrocytes, astrocytes, neurons, and
expression went higher from left to right. A high enrichment score
score indicates the reverse.
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nosis of BMP4 overexpressed patients.
Conclusions
BMP4 was preferentially expressed in LGGs, IDH1 mu-
tation patients, Proneural subtype and G1 subtype. And
it was associated with the better prognosis in grade III
and grade IV gliomas, all of which suggested that BMP4
was a novel biomarker with potential important thera-
peutic implications.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZB and CZ made an equal contribution in data analysis and manuscript
planning and writing. WY participated manuscript writing and approved the
final version. YL and ML were responsible for IHC. WZ and TJ revised the
manuscript critically. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from 1. National High Technology
Research and Development Program (No.2012AA02A508) 2. International
Science and Technology Cooperation Program (No. 2012DFA30470)
3. National Natural Science Foundation of China (No. 81201993) 4. National
973 program (No.2011CB707804).
Received: 28 February 2013 Accepted: 11 April 2013
Published: 16 April 2013
References
1. Wang Y, Jiang T: Understanding High Grade Glioma: Molecular
Mechanism, Therapy and Comprehensive Management. Cancer Lett 2013,
331:139–46.
2. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL,
Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, et al: Genetic
pathways to glioblastoma: a population-based study. Cancer Res 2004,
64:6892–6899.
3. Katagiri T, Tsukamoto S: The unique activity of bone morphogenetic
proteins in bone: a critical role of the Smad signaling pathway. Biol Chem
2013. doi:10.1515/hsz-2012-0310. pii: /j/bchm.just-accepted/hsz-2012-0310/
hsz-2012-0310.xml. [Epub ahead of print] PubMed PMID: 23324379.
4. Li Z, Chen YG: Functions of BMP signaling in embryonic stem cell fate
determination. Exp Cell Res 2013, 319:113–119.
5. Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, Baron AT, Schwartz P,
Maihle NJ, Huang Y: Lin28 regulates BMP4 and functions with Oct4 to
affect ovarian tumor microenvironment. Cell Cycle 2013, 12:88–97.
6. Fernandez-Rozadilla C, Palles C, Carvajal-Carmona L, Peterlongo P, Nici C,
Veneroni S, Pinheiro M, Teixeira MR, Moreno V, Lamas MJ, et al: BMP2/BMP4
colorectal cancer susceptibility loci in northern and southern European
populations. Carcinogenesis 2013, 34:314–8.
7. Zhou Z, Chen ZW, Yang XH, Shen L, Ai XH, Lu S, Luo QQ: Establishment of
a biomarker model for predicting bone metastasis in resected stage III
non-small cell lung cancer. J Exp Clin Cancer Res 2012, 31:34.
8. Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C,
Kang C, et al: Molecular classification of gliomas based on whole genome
gene expression: a systematic report of 225 samples from the Chinese
Glioma Cooperative Group. Neuro Oncol 2012, 14:1432–1440.
9. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR,
Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies
clinically relevant subtypes of glioblastoma characterized by abnormalities
in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98–110.
10. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm
JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al: Intrinsic gene
expression profiles of gliomas are a better predictor of survival than
histology. Cancer Res 2009, 69:9065–9072.
11. Hanzelmann S, Castelo R, Guinney J: GSVA: gene set variation analysis for
microarray and RNA-Seq data. BMC Bioinforma 2013, 14:7.12. R Core Team: A language and environment for statistical computing. Vienna,
Austria: R Foundation for Statistical Computing; 2012.
13. Castelo R: GSVAdata: Data employed in the vignette of the GSVA package.
14. Kelleher FC, Fennelly D, Rafferty M: Common critical pathways in
embryogenesis and cancer. Acta Oncol 2006, 45:375–388.
15. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S,
Chandler I, Vijayakrishnan J, Sullivan K, Penegar S, et al: Meta-analysis of
genome-wide association data identifies four new susceptibility loci for
colorectal cancer. Nat Genet 2008, 40:1426–1435.
16. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R,
Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO: Bone
morphogenetic protein antagonist gremlin 1 is widely expressed by
cancer-associated stromal cells and can promote tumor cell proliferation.
Proc Natl Acad Sci USA 2006, 103:14842–14847.
17. Kwak C, Park YH, Kim IY, Moon KC, Ku JH: Expression of bone
morphogenetic proteins, the subfamily of the transforming growth
factor-beta superfamily, in renal cell carcinoma. J Urol 2007,
178:1062–1067.
18. Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A: Bone
morphogenetic protein-4 inhibits proliferation and induces apoptosis of
multiple myeloma cells. Blood 2001, 97:516–522.
19. Virtanen S, Alarmo EL, Sandstrom S, Ampuja M, Kallioniemi A: Bone
morphogenetic protein -4 and -5 in pancreatic cancer–novel
bidirectional players. Exp Cell Res 2011, 317:2136–2146.
20. Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A: Parallel inhibition of
cell growth and induction of cell migration and invasion in breast
cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat
2010, 124:377–386.
21. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW: BMP4 induces
EMT and Rho GTPase activation in human ovarian cancer cells.
Carcinogenesis 2007, 28:1153–1162.
22. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H,
Olivi A, Dimeco F, Vescovi AL: Bone morphogenetic proteins inhibit the
tumorigenic potential of human brain tumour-initiating cells.
Nature 2006, 444:761–765.
23. Piccirillo SG, Vescovi AL: Bone morphogenetic proteins regulate
tumorigenicity in human glioblastoma stem cells. Ernst Schering Found
Symp Proc 2006, 6:59–81.
24. Altaner C: Glioblastoma and stem cells. Neoplasma 2008, 55:369–374.
25. Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W, Pu Y, You Y, Yang Z, Liu N:
Bone morphogenetic protein 4 inhibits cell proliferation and induces
apoptosis in glioma stem cells. Cancer Biother Radiopharm 2011, 26:77–83.
26. Liu B, Tian D, Yi W, Wu L, Cai Q, Dong H, Shen H, Ji B, Wang L, Zhang S,
et al: Effect of bone morphogenetic protein 4 in the human brain glioma
cell line U251. Cell Biochem Biophys 2010, 58:91–96.
27. Kallioniemi A: Bone morphogenetic protein 4-a fascinating regulator of
cancer cell behavior. Cancer Genet 2012, 205:267–277.
doi:10.1186/1479-5876-11-100
Cite this article as: Bao et al.: BMP4, a strong better prognosis predictor,
has a subtype preference and cell development association in gliomas.
Journal of Translational Medicine 2013 11:100.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
